Hyperglycemia as a Risk Factor for Cancer Progression

Cancer cell proliferation

Enhanced glucose uptake in cancer cells is a well-established hallmark of cancer cells [14]. The enhanced glucose metabolism in cancer cells is referred to as the Warburg effect, which comprises the increase in aerobic glycolysis in cancer cells defined by Warburg [15]. In this respect, hyperglycemia could provide a high glucose fuel source for cancer cells supporting rapid proliferation. Indeed, in vitro studies with cancer cell lines indicate that high concentrations of glucose levels regulate enhanced expression of genes associated with promoting cancer cell proliferation, invasion, and migration [16]. In vivo animal studies are plagued by technical limitations to evaluate the effects of hyperglycemia on cancer cells. This is due to the fact that in order to induce hyperglycemia in these rodent models, streptozotocin is used to destroy pancreatic β-cells. This leads to hyperglycemia, but obviously also prompts the loss of insulin in circulation. Insulin is an intrinsic mitogen affecting tumor growth. In humans, elevated glucose levels in circulation serve as an established predictor of poor survival in cancer patients [17,18,19]. In line with that, high sugar intake is associated with increased cancer cell proliferation [16].

Multiple proteins have been implicated as mediators of hyperglycemia and cancer cell proliferation (Fig. 1). Recent in vitro studies suggest that the expression of glucose transporters, such as the GLUT1 and GLUT3 isoforms, is regulated under hyperglycemic conditions in JAR cells, a choriocarcinoma cell line [20]. Hyperglycemic conditions in vitro (such as 25 mM D-glucose) trigger increased glucose uptake in JAR cells due to a transcriptional increase and enhanced protein levels for GLUT1 and GLUT3 [20]. Growth factors, such as epidermal growth factor (EGF) levels are augmented by high glucose treatment in pancreatic cancer cell lines, such as BxPC-3 and Panc-1, and subsequently activate its receptor, the epidermal growth factor receptor (EGFR), a well-known oncogenic pathway [21]. In addition, the levels of protein kinase C (PKC) and peroxisome proliferator-activated receptors (PPARs) are stimulated under hyperglycemic conditions in MCF-7 human breast cancer cells [22]. Overexpression of PKC-α in MCF-7 induces a more aggressive phenotype [23]. PPAR-α and PPAR-γ are influencing lipid metabolic pathways. High levels of PPAR-α and PPAR-γ can accelerate cell proliferation [24]. High glucose accelerates the cell cycle through regulating the levels of key proteins, such as cyclin-dependent kinase 2, E2F, cyclinA, and cyclinE, resulting in increased proliferation [16]. Furthermore, hyperglycemic conditions augment the levels of glial cell line derived neurotophic factor (GDNF) and its tyrosine kinase receptor gene, the rearranged during transfection (RET) gene, in human pancreatic cancer cells, such as BxPC-3 and MIA PaCa-2 cells [25]. GDNF is a cytokine related to the transforming growth factor-β family, enhancing the survival and differentiation of midbrain dopaminergic neurons [26] as well as promoting pancreatic cancer cell proliferation and invasion mediated through a protein complex of RET/GDNF-family receptor α-1 (GFR α-1) [27]. Taken together, these data strongly implicate hyperglycemia as a contributing factor leading to enhanced cell proliferation.

Fig. 1

Impact of hyperglycemia on tumor progression. A hyperglycemic environment contributes to tumor progression through multiple pathways. Cancer cell proliferation is promoted by the up-regulation of glucose transporters (GLUT1 and GLUT3), epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR), and other growth promoting signals such as protein kinase C-α (PKC-α), peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ, glial cell line-derived neurotophic factor (GDNF), and its receptor, rearranged during transfection (RET) receptor. The levels of hypoxia inducible factor-1α (HIF1α), prolyl hydroxylase (PHD) enzyme and cytochrome c regulated by hyperglycemia are associated with antiapoptotic activity of cancer cells. Cancer cell migration and invasiveness is acquired by the up-regulation of superoxide dismutase (SOD), urokinase plasminogen activator (uPA), ZRT/IRT-like protein 6 (ZIP6), and ZRT/IRT-like protein 10 (ZIP10). Moreover, hyperglycemic memory, i.e., epigenetic regulation of cancer cells by hyperglylcemia, increases the expression of nuclear factor-κB (NF-κB) and neuregulin-1 (Nrg1), both are well-established oncogenic signals.

Cancer cell antiapoptosis

Apoptosis, the process of programmed cell death, is a genetically regulated process that is essential for multicellular organisms. The dysregulation of apoptosis can result in uncontrolled cellular growth [28]. The connection between hyperglycemia and cancer cell apoptosis is unclear; however, there are several possible connections suggested (Fig. 1).

Many tumors are exposed to hypoxia due to limited oxygen supplies during rapid anabolic cell proliferation [29]. In response to hypoxia, hypoxia inducible factor-1α (HIF1α), a key transcriptional regulator of the hypoxic response, is stabilized at the protein level and translocated into nucleus. This leads to the increased expression of genes associated with glucose metabolism, angiogenesis and survival/antiapoptotic processes [30,31]. Under normoxic conditions, HIF1α is degraded by HIF prolyl hydroxylase (PHD) enzymes, and this process is oxygen dependent [31]. Hyperglycemia regulates the stability and function of HIF1α through interfering with the degradation of HIF1α by PHD enzymes [32], which causes increased cancer cell survival and conveys antiapoptotic qualities upon the tumor.

Recent studies also suggest that glucose metabolism in cancer cells protects cytochrome c-mediated apoptosis [33]. Glutathione is one of the main antioxidant mediators of cells, which is reduced by nicotinamide adenine dinucleotide phosphate (NADPH) derived from enhanced glucose metabolism, such as the pentose phosphate pathway [34].

Cancer cell migration and invasiveness

Epidemiological data suggest that metastatic growth is the main cause of deaths in 90% patients carrying solid tumors [35]. Metastatic growth ensues when cancer cells become invasive through an altered phenotype, penetrating into the circulatory system, and taking hold in a distant organ. Epithelial-mesenchymal transition (EMT), a multifaceted process critical for the acquisition of migration, invasiveness and pluripotent stem cell-like phenotype, plays a pivotal role in the metastatic process [36]. Several studies suggest that high glucose induces cancer cell invasiveness and migration through stimulating EMT (Fig. 1). High glucose decreases E-cadherin levels, an epithelial cell marker, and increases the PKC-α pathway, leading to a more invasive phenotype [16]. Recently, Dong et al. [37] suggested that hyperglycemia induces the EMT phenotype and the expression of cancer stem cell markers in basal luminal breast carcinoma, which leads to reduced reactive oxygen species (ROS) generation and increased cell survival.

Hydrogen peroxide has been implicated in the migration and invasive activity of pancreatic cancer cells under hyperglycemic conditions [38]. High glucose levels generate oxidative stress due to ROS. The migration and invasion of pancreatic cancer cell lines, such as BxPC-3 and Panc-1 cells, are all augmented by superoxide dismutase (SOD) which catalyzes the conversion of the superoxide anion to hydrogen peroxide under hyperglycemic conditions [39]. The mRNA expression of urokinase plasminogen activator, one of the mediators involved in cell migration, is also up-regulated under high glucose levels with SOD [40].

Zinc is an essential element for cellular function. An imbalance in zinc homeostasis causes several human diseases [41]. Hyperglycemia is thought to promote migration of breast cancer cells via zinc and its transporters, ZRT/IRT-like protein 6 (ZIP6) and ZRT/IRT-like protein 10 (ZIP10) [42]. Thus, high glucose increases zinc uptake, and the expression of ZIP6 and ZIP10 transporters in breast cancer cells, such as MCF-7. ZIP6 regulates EMT, and ZIP10 is known to be involved in cancer cell migration [43].

Epigenetic regulation in cancer cells

Chronic hyperglycemic conditions may cause epigenetic changes in oncogenic pathways in cancer cells (Fig. 1). A recent study suggested that epigenetic silencing of the critical gluconeogenic enzyme, fructose-1,6-biphosphatase through the EMT-related transcription repressor Snail, increases glycolysis and NADPH production via the pentose phosphate pathway and a reduction in oxidative phosphorylation [37]. These metabolic alterations induced by hyperglycemia contribute to lower ROS generation and increase of β-catenin/TCF4 activation, a key pathway for the acquisition of a cancer stem cell phenotype, leading to better survival [37]. Recent studies show that transient hyperglycemia induces the recruitment of the transcription factor Set7 to the nuclear factor-κB (NF-κB) p65 promoter. The recruitment of Set7 to p65 promoter enhances histone 3 lysine 4 monomethylation within the promoter, resulting in increased NF-κB activation and increased inflammation [44].

Hyperglycemic memory is an epigenetic phenomenon induced by hyperglycemia [12]. After cancer cells are exposed to hyperglycemic conditions, a subset of oncogenic pathways are permanently activated, even after hyperglycemic conditions are normalized to euglycemic conditions [45]. However, the specific molecular mechanism how a cancer cell gets permanently "rewired" and the hyperglycemic memory instilled is still unclear. We suggested that the neuregulin-1 (Nrg1)-HER3 pathway is up-regulated in tumors derived from hyperglycemic patients or rodents. Nrg1 belongs to a family of EGF-like ligands for HER3, itself a member of the EGFR of receptor tyrosine kinase, related to cancer cell proliferation, survival and metastasis [46]. Once activated, these cancer cells originating from hyperglycemic conditions grow faster than control cells even under euglycemic conditions [45].

Therapeutic interventions

Given these strong epidemiological connections seen in patients suffering from DM with a higher risk to develop some types of cancer, these increased risks need to be taken into account and prophylactic screening is warranted. However, an additional question is whether antidiabetic therapeutic approaches also reduce the risk of associated cancers.

There are a variety of antidiabetic interventions, including sulfonylureas, α-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs) [47]. The major groups of antidiabetic drugs increase the level of circulating insulin, thereby reducing hyperglycemia by various mechanisms. Especially, compounds such as metformin inhibit hepatic gluconeogenesis to reduce the level of circulating glucose and increasing insulin sensitivity through the 5'AMP-activated protein kinase and AKT/mTOR pathway [48,49,50]. Metformin has received widespread attention due to its apparent anticancer effects [48,51]. Metformin inhibits cell proliferation and induces apoptosis in cancer cell lines [52,53,54]. It can also exert anticancer effects via modulation of DICER (also known as endoribonuclease Dicer or helicase with RNase motif) activity, via mir33a up-regulation, and via targeting c-MYC (Myc proto-oncogene protein) [55]. Despite a lot of excitement and attention, clinical data inferring anti-mitogenic effects of antidiabetic drugs and their effects on cancer incidence and mortality remain somewhat controversial. As such, some studies suggest that insulin and insulin glargine can increase cancer incidence [56,57], while other studies conclude that there is no effect [58]. Similarly, TZDs have been reported to exert both tumor growth supporting and inhibitory roles [59], whereas metformin and other biguanides decrease the cancer incidence [60,61] or have no impact [62].

Another drawback of treating cancers in the context of DM is at the level of the memory effects of hyperglycemia and the associated epigenetic alterations in key oncogenic pathways in cancer cells. Thus, merely managing blood glucose levels per se might not be sufficient to obtain a full therapeutic impact. We need to expand our understanding of the key specific target genes and pathways affected by hyperglycemia within tumors, such that these pathways may be targeted in a more directed approach. For instance, the finding that the NRG1/HER3 axis is specifically and disproportionately activated in women diagnosed with breast cancer and found to be hyperglycemic at the time of diagnosis may suggest an effective first line of treatment with neutralizing Her3 antibodies which would not necessarily be the first choice in the context of other types of breast cancer.